Incyte's new CEO, Bill Meury, signals a potential strategic pivot toward M&A, leveraging his biopharma acquisition experience ...

The finding that basophil counts may have prognostic significance aligns with a growing body of research into basophils in ...

During a live event, Mojtaba Akhtari, MD, discussed trials studying patients with high-risk polycythemia vera.

Illinois Municipal Retirement Fund lessened its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) ...

Incyte INCY has put up a good performance in the past three months. Shares of the company have gained 9.2% against the ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

As practicing oncologists, we can get bogged down in our individual practices and thus have trouble seeing the bigger picture ...

Panelists discuss how to approach a 67-year-old man with advanced polycythemia vera who is resistant to hydroxyurea, ...

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS ...

Protagonist Therapeutics Inc. (NASDAQ:PTGX) is one of the best mid cap growth stocks to invest in now. Just as June began, ...